New Data Show Patients Treated with First-in-Class TREMFYA ® (guselkumab) Achieve Durable Efficacy Across Joint and Axial Symptoms of Active Psoriatic Arthritis Through Two Years
SPRING HOUSE, PENNSYLVANIA, June 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from Phase 3 studies demonstrating patients treated with TREMFYA® (guselkumab) achieved consistent, long-term efficacy through two years across the domains of active psoriatic arthritis (PsA) – including joint, skin, enthesitis,a dactylitis,b spinal pain and disease severityc endpoints – irrespective of baseline characteristics.1 Further analyses showed TREMFYA also provided patients with sustained improvements in measures of health-related quality of life (HRQoL), including fatigue, pain...
Source: Johnson and Johnson - June 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Eosinophilic Diseases Often Overlap, Raising Costs Eosinophilic Diseases Often Overlap, Raising Costs
Overlap was less common in eosinophilic esophagitis but more common in eosinophilic gastritis/eosinophilic gastroenteritis.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - May 27, 2022 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news
1 Dirty Pool, Many Cases of E. Coli: Summer's Swimming Danger
MONDAY, May 23, 2022 -- As the weather warms and families flock to pools, dirty water may dampen the fun.
Swimmers at a Pennsylvania community pool learned that the hard way when in June 2021 more than a dozen kids were seriously sickened by two... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 23, 2022 Category: General Medicine Source Type: news
Notes from the Field: Escherichia coli O157:H7 Outbreak in Children with Clostridioides difficile Colonization Associated with an Improperly Treated Swimming Pool - Pennsylvania, June 2021
This report describes an E. coli outbreak associated with a swimming pool. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - May 19, 2022 Category: American Health Tags: C. difficile Children's Health Clostridium difficile Infection E. coli Infection MMWR Morbidity & Mortality Weekly Report Outbreaks Recreational Water Illness (RWI) Water Treatment Water-Related Diseases Source Type: news
New Data Show TREMFYA ® (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a Differentiated Mechanism from Risankizumab
SPRING HOUSE, PENNSYLVANIA, May 18, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the first results of the in vitro MODIF-Y studies, supporting a hypothesis that may differentiate the mechanism of first-in-class TREMFYA® (guselkumab) from risankizumab due to the ability of TREMFYA to bind to CD64 positive (CD64+) cells in addition to interleukin (IL)-23 — both of which are key components of the immune system. 1,2 These findings, which are being presented at the Society for Investigative Dermatology (SID) annual meeting May 18-21, 2022 in Portland, Oregon, demonstrate TREMFYA bind...
Source: Johnson and Johnson - May 18, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Increasing usage of chlorhexidine in health care settings: blessing or curse? A narrative review of the risk of chlorhexidine resistance and the implications for infection prevention and control
This study reviewed the published data regarding the evidence of reduced CHG susceptibility, the cross-resistance with antibiotics, and the implications for infection control for S. aureus, coagulase-negative staphylococci, E. coli, K. pneumoniae, and P. aeruginosa. Despite incongruity in definitions of " resistance, " 12 increased CHG minimal inhibitory values of these pathogens have been described, and different mutations encoding for CHG efflux pumps have been identified. Clinical relevance of species with reduced susceptibility to CHG is debatable and cross-resistance with antibiotics remains controversial. However, so...
Source: Current Awareness Service for Health (CASH) - May 17, 2022 Category: Consumer Health News Source Type: news
New jab to help prevent urinary tract infections
In the coming months, the jab will be offered in a number of NHS hospitals as part of a landmark trial that will assess whether a single injection can stop cases caused by the common bacteria E. Coli. (Source: the Mail online | Health)
Source: the Mail online | Health - May 7, 2022 Category: Consumer Health News Source Type: news
Researcher, 26, left feeling so sick he 'wanted to die' after drinking shot of shigella
Jack Eberts, from Washington D.C., drunk a shot of the dysentery-causing bacteria for a vaccine trial. He became so ill that he faced stomach cramps, diarrhea, and even soiled himself. (Source: the Mail online | Health)
Source: the Mail online | Health - May 3, 2022 Category: Consumer Health News Source Type: news
Over 120,000 pounds of ground beef is recalled over E.coli contamination fears
The U.S. Food Safety and Inspection Service urged Americans who had contaminated burgers and ground beef to throw them out or take them back to the store. Products came from a facility in New Jersey. (Source: the Mail online | Health)
Source: the Mail online | Health - April 27, 2022 Category: Consumer Health News Source Type: news
Over 120,000 pounds of ground beef recalled over possible E.coli contamination
Over 120,000 pounds of ground beef products are being recalled by the company due to a possible E.Coli contamination. #groundbeefproducts (Source: Reuters: Health)
Source: Reuters: Health - April 27, 2022 Category: Consumer Health News Source Type: news
Ground Beef Recall, Over 120,000 Pounds, Due To E. Coli Concerns
Routine U.S. Department of Agriculture ’s (USDA’s) Food Safety and Inspection Service (FSIS) testing found E. coli O103 in a Lakeside Refrigerated Services facility. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - April 27, 2022 Category: Pharmaceuticals Authors: Bruce Y. Lee, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation Business /business Food & Drink /food-drink Editors' Pick editors-pick pharma Source Type: news
Microplastics in Seawater May Harbor Parasites
Laboratory experiments find that Toxoplasma, Cryptosporidium, and Giardia can congregate on microplastic beads and fibers, suggesting they might make their way into and around the world ’s oceans by... (Source: The Scientist)
Source: The Scientist - April 26, 2022 Category: Science Tags: News & Opinion Source Type: news
Johnson & Johnson Launches Next Satellite Center for Global Health Discovery at Holistic Drug Discovery and Development Centre, University of Cape Town, Focused on Antimicrobial Resistance (AMR)
Cape Town, South Africa, April 25, 2022 – Johnson & Johnson (the Company) today announced the launch of the J&J Satellite Center for Global Health Discovery (Satellite Center) at the Holistic Drug Discovery and Development (H3D) Centre, University of Cape Town, in Cape Town, South Africa. This marks the latest expansion of the J&J Centers for Global Health Discovery (J&J Centers), a global network of research collaborations between the Company and leading research institutions to accelerate translational and discovery research to address some of the world’s most pressing global health challenges. The Sa...
Source: Johnson and Johnson - April 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Stomach Flu (Gastroenteritis)
Title: Stomach Flu (Gastroenteritis)Category: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 4/14/2022 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - April 14, 2022 Category: Nutrition Source Type: news
